Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Current Leases (2019 - 2025)

Historic Current Leases for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to $1.1 million.

  • Madrigal Pharmaceuticals' Current Leases rose 2334.85% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 2334.85%. This contributed to the annual value of $983000.0 for FY2024, which is 8652.75% up from last year.
  • According to the latest figures from Q3 2025, Madrigal Pharmaceuticals' Current Leases is $1.1 million, which was up 2334.85% from $1.0 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Current Leases high stood at $1.1 million for Q3 2025, and its period low was $320000.0 during Q1 2021.
  • Moreover, its 5-year median value for Current Leases was $557000.0 (2024), whereas its average is $652894.7.
  • Its Current Leases has fluctuated over the past 5 years, first soared by 11811.41% in 2022, then tumbled by 5324.23% in 2023.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Current Leases stood at $410000.0 in 2021, then soared by 46.83% to $602000.0 in 2022, then fell by 12.46% to $527000.0 in 2023, then surged by 86.53% to $983000.0 in 2024, then grew by 10.17% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.0 million for Q2 2025, and $1.0 million during Q1 2025.